01—Abstract
Summary
Summary of the 10-Q filed November 5, 2025. Cited figures are marked; the original filing is the authoritative source.
Royalty Pharma plc (RPRX) reported third-quarter 2025 consolidated net income of $444.2 milliona, compared with $806.4 million in the third quarter of 2024, and net income attributable to Royalty Pharma plc of $288.2 million versus $544.0 million.
Basic EPS was $0.67b versus $1.22. The decline was driven mainly by a swing in the provision for changes in expected cash flows (a $12.1 million expense in Q3 2025 versus $227.6 million of income in Q3 2024), higher share-based compensation of $73.4 million following the May 16, 2025 Internalization, and R&D funding expense of $50.5 million. Income from financial royalty assets rose 8.6% to $578.8 million, and Portfolio Receipts rose 10.8% to $813.6 million for the quarter.
For the first nine months, total income and other revenues were $1.76 billionc and net income attributable to Royalty Pharma plc was $556.7 million. The company completed the Internalization of its former external manager, recording goodwill of $924.6 million and a $379.9 million... [note: term loan of $380 million assumed]. Share-based compensation now includes $76.5 million related to RP Holdings Class E Interests and $84.7 million related to Employee EPAs for the nine months, with approximately $678.9 million and $71.5 million of unrecognized expense, respectively.
Total debt principal was $9.18 billiond at September 30, 2025, up from $7.8 billion at year-end 2024, after issuing $2.0 billion of senior unsecured notes in September 2025 and repaying $1.0 billion of notes. Capital deployment remained active: the company invested $1.7 billion in royalties, milestones and other contractual receipts in the first nine months of 2025, including the $885 million BeOne Imdelltra royalty and up to $2 billion of Revolution Medicines funding. Repurchases totaled 35.4 million Class A shares for about $1.2 billion in the first nine months, with approximately $1.9 billion remaining under the authorization.
A subsequent event was the November 2025 acquisition of an Amvuttra royalty from Blackstone for $310 million. The company also disclosed that Vertex has not paid the full amount of Alyftrek royalties the company believes it is contractually owed, and that it has begun dispute resolution procedures.
02—Key points
Key Highlights
- Q3 2025 net income attributable to Royalty Pharma plc was $288.2 million ($0.67 basic EPS), down from $544.0 million ($1.22) in Q3 2024.
- Income from financial royalty assets increased 8.6% to $578.8 million in Q3 2025; Portfolio Receipts increased 10.8% to $813.6 million.
- Provision for changes in expected cash flows was a $12.1 million expense in Q3 2025 versus $227.6 million of income in Q3 2024, adding volatility to reported earnings.
- G&A expenses rose to $118.7 million in Q3 2025 (up 109.3%), including $73.4 million of share-based compensation tied to the May 2025 Internalization.
- Total debt principal rose to $9.18 billion at September 30, 2025, after $2.0 billion of new senior notes issued in September 2025.
- The company repurchased 35.4 million Class A shares for about $1.2 billion in the first nine months of 2025, with about $1.9 billion remaining under its authorization.
- Vertex has not paid the full amount of Alyftrek royalties the company believes it is contractually entitled to; dispute resolution procedures have been commenced.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-QQ3 FY2025filed November 5, 2025Financial Statements
Q3 FY2025 against Q3 FY2024
| Line item | Q3 FY2025Q3 FY2024 | Change |
|---|---|---|
| Revenue | $609.29M$564.69M | +7.9% |
| R&D Expenses | $50.50M$500K | +10000.0% |
| Operating Expenses | $182.13M-$170.38M | +206.9% |
| Operating Income | $427.16M$735.07M | −41.9% |
| Net Income | $288.22M$543.99M | −47.0% |
| EPS (Basic) | $0.67$1.22 | −45.1% |
| EPS (Diluted) | $0.67$1.21 | −44.6% |
| Shares Outstanding (Basic) | 431.89M447.63M | −3.5% |
| Shares Outstanding (Diluted) | 559.61M592.73M | −5.6% |
05—Questions
Frequently Asked Questions
Why did net income fall so sharply compared with the third quarter of 2024?
Q3 2024 included $227.6 million of provision income for changes in expected cash flows, while Q3 2025 recorded a $12.1 million provision expense. Share-based compensation also rose by $72.2 million after the Internalization, and R&D funding expense increased to $50.5 million from $0.5 million.
What was the financial impact of the Internalization?
The company acquired RP Manager on May 16, 2025 for a total purchase price of $565.2 million and recorded goodwill of $924.6 million. It assumed a $380 million term loan and no longer pays Operating and Personnel Payments to the Legacy Manager. Share-based compensation now includes amortization of RP Holdings Class E Interests and Employee EPAs.
How is the company funding its royalty acquisitions and shareholder returns?
The company relies on operating cash flow, which was $1.66 billion in the first nine months of 2025, and on debt. It issued $2.0 billion of senior unsecured notes in September 2025, repaid $1.0 billion of notes, and had $938.9 million of cash and cash equivalents at quarter end. It also had $1.8 billion of available revolving commitments and paid $284.0 million in dividends in the first nine months.
What is the Vertex dispute about?
Beginning in the second quarter of 2025, Royalty Pharma did not receive from Vertex the full amount of royalty receipts on Alyftrek net sales that it believes it is contractually entitled to. The company has commenced dispute resolution procedures, and any amounts receivable will be recognized only upon resolution in its favor.
What notable transactions occurred after the quarter ended?
In November 2025, the company acquired a royalty interest in Amvuttra from Blackstone for $310 million. In October 2025 it also funded the $100 million tranche five draw requested by Cytokinetics.
06—Continue